Madras HC: Police Superintendent not Liable For IO’s Delay In Filing Chargesheet or Closure Report  ||  Supreme Court: Provident Fund Dues Have Priority over a Bank’s Claim under the SARFAESI Act  ||  SC Holds Landowners Who Accept Compensation Settlements Cannot Later Seek Statutory Benefits  ||  Supreme Court: Endless Investigations and Long Delays in Chargesheets Can Justify Quashing  ||  Delhi HC: Arbitrator Controls Evidence and Appellate Courts Cannot Reassess Facts  ||  Delhi HC: ED Can Search Anyone Holding Crime Proceeds, not Just Those Named in Complaint  ||  Delhi HC: ED Can Search Anyone Holding Crime Proceeds, not Just Those Named in Complaint  ||  Delhi HC: Economic Offender Cannot Seek Travel Abroad For Medical Treatment When Available In India  ||  SC: Governors and President Have No Fixed Timeline To Assent To Bills; “Deemed Assent” is Invalid  ||  SC: Assigning a Decree For Specific Performance of a Sale Agreement Does Not Require Registration    

CCI approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.- (Press Information Bureau) (16 Mar 2022)

MANU/PIBU/0878/2022

MRTP/ Competition Laws

The Competition Commission of India (CCI) approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.

The proposed combination pertains to the proposed acquisition of minority stake in Micro Life Sciences Private Limited (Micro Life/ Target) by South Elm Investments B.V. (SEI/ Acquirer).

SEI is an investment holding company incorporated under the laws of Netherlands. The shareholders of SEI are certain private equity funds managed by Warburg Pincus LLC.

Target is a company incorporated in India, which is primarily engaged in the following business activities in India along with subsidiaries: manufacture and sale of (a) medical devices in various categories such as stents, Percutaneous Transluminal Coronary Angioplasty catheters, heart valves, orthopedic implants, and endo-surgery products (such as sutures, staplers, meshes and intrauterine devices); (b) in-vitro diagnostics analyzers and reagents; and (c) over the counter (OTC) products like products COVID self-test kits and pregnancy test kits, in India. The Target (through its subsidiaries) is engaged in the B2C sale of certain specialized medical devices (such as surgical robots and ultrasonic energy devices) to hospitals and has research and development (R&D) facilities for in-vitro diagnostic, orthopedic, endo-surgery and cardiovascular solutions.

Tags : ACQUISITION   APPROVAL   MINORITY STAKE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved